- Home
- U vs LEGN Comparison
U vs LEGN Comparison
Compare U & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- U
- LEGN
- Stock Information
- Founded
- U 2004
- LEGN 2014
- Country
- U United States
- LEGN United States
- Employees
- U N/A
- LEGN N/A
- Industry
- U Retail: Computer Software & Peripheral Equipment
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- U Technology
- LEGN Health Care
- Exchange
- U Nasdaq
- LEGN Nasdaq
- Market Cap
- U 7.7B
- LEGN 7.0B
- IPO Year
- U 2020
- LEGN 2020
- Fundamental
- Price
- U $21.96
- LEGN $31.08
- Analyst Decision
- U Buy
- LEGN Strong Buy
- Analyst Count
- U 13
- LEGN 13
- Target Price
- U $23.79
- LEGN $79.42
- AVG Volume (30 Days)
- U 8.4M
- LEGN 1.6M
- Earning Date
- U 05-07-2025
- LEGN 05-13-2025
- Dividend Yield
- U N/A
- LEGN N/A
- EPS Growth
- U N/A
- LEGN N/A
- EPS
- U N/A
- LEGN N/A
- Revenue
- U $1,787,875,000.00
- LEGN $728,303,000.00
- Revenue This Year
- U N/A
- LEGN $65.96
- Revenue Next Year
- U $9.92
- LEGN $52.55
- P/E Ratio
- U N/A
- LEGN N/A
- Revenue Growth
- U N/A
- LEGN 112.46
- 52 Week Low
- U $13.90
- LEGN $29.27
- 52 Week High
- U $30.88
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- U 57.08
- LEGN 39.41
- Support Level
- U $19.81
- LEGN $30.25
- Resistance Level
- U $22.20
- LEGN $33.30
- Average True Range (ATR)
- U 1.01
- LEGN 1.53
- MACD
- U 0.08
- LEGN -0.18
- Stochastic Oscillator
- U 74.32
- LEGN 26.21
About U Unity Software Inc.
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and other Americas, and key revenue is derived from the EMEA region. The products are used in the gaming industry, retail, automotive, architecture, engineering, and construction.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.